KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Amortization - Intangibles (2019 - 2022)

Royalty Pharma (RPRX) has disclosed Amortization - Intangibles for 4 consecutive years, with $5.7 million as the latest value for Q1 2022.

  • Quarterly Amortization - Intangibles changed 0.02% to $5.7 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Dec 2022, down 75.34% year-over-year, with the annual reading at $5.7 million for FY2022, 75.34% down from the prior year.
  • Amortization - Intangibles hit $5.7 million in Q1 2022 for Royalty Pharma, down from $5.8 million in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $5.8 million in Q3 2019 to a low of $5.7 million in Q1 2022.
  • Historically, Amortization - Intangibles has averaged $5.8 million across 4 years, with a median of $5.8 million in 2019.
  • Biggest five-year swings in Amortization - Intangibles: changed 0.0% in 2020 and later fell 1.08% in 2021.
  • Year by year, Amortization - Intangibles stood at $5.8 million in 2019, then changed by 0.0% to $5.8 million in 2020, then changed by 0.0% to $5.8 million in 2021, then decreased by 2.17% to $5.7 million in 2022.
  • Business Quant data shows Amortization - Intangibles for RPRX at $5.7 million in Q1 2022, $5.8 million in Q4 2021, and $5.8 million in Q3 2021.